{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T15:20:52Z","timestamp":1780932052043,"version":"3.54.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.clgc.2021.04.007","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T17:12:07Z","timestamp":1618938727000},"page":"434-446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["A Phase I\/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma"],"prefix":"10.1016","volume":"19","author":[{"given":"Simon","family":"Chowdhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery R","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Perini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Arkenau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Voskoboynik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Aimone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Naeije","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Reising","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2675-5095","authenticated-orcid":false,"given":"David F","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2021.04.007_bib0001","first-page":"7","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2021.04.007_bib0002","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing's syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clgc.2021.04.007_bib0003","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0022-5347(05)68049-4","article-title":"Vascular endothelial growth factor as prognostic factor in renal cell carcinoma","volume":"163","author":"Jacobsen","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2021.04.007_bib0004","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1309\/LQ9EMK8QKE75NGGX","article-title":"Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma","volume":"120","author":"Sulzbacher","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clgc.2021.04.007_bib0005","first-page":"4233","article-title":"Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis","volume":"54","author":"Takahashi","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2021.04.007_bib0006","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1620\/tjem.195.101","article-title":"Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma","volume":"195","author":"Tsuchiya","year":"2001","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.clgc.2021.04.007_bib0007","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.clgc.2021.04.007_bib0008","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clgc.2021.04.007_bib0009","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2002-12-3738","article-title":"Synergy between tumor immunotherapy and antiangiogenic therapy","volume":"102","author":"Nair","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clgc.2021.04.007_bib0010","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.clgc.2021.04.007_bib0011","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.3389\/fimmu.2018.03120","article-title":"The evolving landscape of immunotherapy-based combinations for frontline treatment of advanced renal cell carcinoma","volume":"9","author":"Amin","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clgc.2021.04.007_bib0012","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.04.007_bib0013","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.04.007_bib0014","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.04.007_bib0015","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/jco.2013.31.15_suppl.3000","article-title":"A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors","volume":"31","author":"Herbst","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.04.007_bib0016","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.04.007_bib0017","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2018.36.15_suppl.4500","article-title":"Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort A of KEYNOTE-427","volume":"36","author":"McDermott","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.04.007_bib0018","doi-asserted-by":"crossref","first-page":"viii303","DOI":"10.1093\/annonc\/mdy283.080","article-title":"KEYNOTE-427 Cohort A: pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)","volume":"29","author":"Donskov","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2021.04.007_bib0019","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study","volume":"34","author":"McDermott","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.04.007_bib0020","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.ejca.2015.08.017","article-title":"Efficacy of targeted therapies after PD-1\/PD-L1 blockade in metastatic renal cell carcinoma","volume":"51","author":"Albiges","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2021.04.007_bib0021","unstructured":"US Food & Drug Administration. Votrient (pazopanib) prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/022465s029lbl.pdf. Accessed: March 1, 2021."},{"key":"10.1016\/j.clgc.2021.04.007_bib0022","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.04.007_bib0023","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1200\/JCO.2017.35.15_suppl.4506","article-title":"A phase I\/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC)","volume":"35","author":"Chowdhury","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.04.007_bib0024","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.04.007_bib0025","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.04.007_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.clgc.2021.04.007_bib0027","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/CJI.0b013e3181f4c208","article-title":"A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients","volume":"33","author":"Adotevi","year":"2010","journal-title":"J Immunother"},{"key":"10.1016\/j.clgc.2021.04.007_bib0028","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.lungcan.2019.07.004","article-title":"Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1\u2013positive advanced non\u2013small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies","volume":"135","author":"Nosaki","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clgc.2021.04.007_bib0029","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.04.007_bib0030","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.04.007_bib0031","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2021.04.007_bib0032","doi-asserted-by":"crossref","first-page":"S1142","DOI":"10.1016\/j.annonc.2020.08.2257","article-title":"Nivolumab\u00a0+\u00a0cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2021.04.007_bib0033","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2021.04.007_bib0034","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s40425-018-0420-0","article-title":"Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study","volume":"6","author":"Amin","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2021.04.007_bib0035","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2021.04.007_bib0036","first-page":"99","article-title":"Combination immunotherapy in renal cell carcinoma","author":"Drake","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clgc.2021.04.007_bib0037","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.ejca.2015.03.019","article-title":"Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients","volume":"51","author":"Powles","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2021.04.007_bib0038","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1200\/jco.2015.33.15_suppl.5599","article-title":"The use of adjuvant treatment in stage I endometrioid endometrial cancer in the National Cancer Database (NCDB)","volume":"33","author":"Jain","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.04.007_bib0039","first-page":"4043","article-title":"Chronic active hepatitis induced by pazopanib mimicking hypervascular liver metastases in a patient with recurrent soft tissue sarcoma: a case report","volume":"16","author":"Ezponda","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.clgc.2021.04.007_bib0040","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/iju5.12101","article-title":"Delayed nivolumab-induced hepatotoxicity during pazopanib treatment for metastatic renal cell carcinoma: an autopsy case","volume":"2","author":"Todo","year":"2019","journal-title":"IJU Case Rep"},{"key":"10.1016\/j.clgc.2021.04.007_bib0041","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000481795","article-title":"Pazopanib-induced hepatotoxicity in an experimental rat model","volume":"63","author":"Cetin","year":"2018","journal-title":"Chemotherapy"},{"key":"10.1016\/j.clgc.2021.04.007_bib0042","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.clgc.2019.09.013","article-title":"Pazopanib-induced liver toxicity in patients with metastatic renal cell carcinoma: effect of UGT1A1 polymorphism on pazopanib dose reduction, safety, and patient outcomes","volume":"18","author":"Henriksen","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2021.04.007_bib0043","doi-asserted-by":"crossref","first-page":"41238","DOI":"10.1038\/srep41238","article-title":"Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity","volume":"7","author":"Choudhury","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.clgc.2021.04.007_bib0044","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1200\/jco.2014.32.15_suppl.5010","article-title":"Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)","volume":"32","author":"Amin","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.04.007_bib0045","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.clgc.2021.04.007_bib0046","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321000926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321000926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:35:25Z","timestamp":1761564925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767321000926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1558767321000926"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2021.04.007","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase I\/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2021.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}